The Medsintez plant took part in the Russia-Africa economic forum held on October 23-24, 2019 in Sochi. The event was attended by leaders of African countries, representatives of Russian, African and international businesses and government entities, as well as representatives of the African continent's integration associations.
The Medsintez plant signed a partnership agreement with a Kenyan company interested in distributing in South Africa the plant’s major products, such as finished forms of genetically engineered human insulin and Triazavirin, an original antiviral drug offering a wide range of antiviral effects. The drug is effective for influenza, ARVI, tick-borne encephalitis and more than 15 other types of viral infections including hemorrhagic fevers.
Also, as a part of the forum, meetings with representatives of ministries of health of Algeria and Tunisia were held, where some issues of drug and medical device circulation in their countries were discussed. Thanks to the Algerian Government's policy, the country's pharmaceutical industry was on a significant rise over recent years. Currently, 150 pharmaceutical production entities are run in Algeria and 51 - in Tunisia. Tunisia's total pharmaceutical production volume is $320M, of which 13% is exported.
The Forum has become a strategically important step towards creating the most favourable conditions for the development of trade and economic relations between the Russian Federation and African countries. It also made it possible to diversify forms and areas of the Russian-African cooperation.
'The Russian Federation traditionally has been actively involved in supporting healthcare development in African countries, and this area remains our priority today too,' says Skvortsova V.I., Minister of Health of the Russian Federation.